Table Of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Multiple Myeloma Market: By Drug Class Segment Market Trends, Size, and Future Outlook
- By Drug Class Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Drug Class Segment Definitions, Technology Landscape
- By Drug Class Segment Market Drivers
- Product Launches
- Technology Launches
- Advances in drug development
- By Drug Class Segment Market Restraints
- High treatment costs
- Adverse effects
Chapter 4. Multiple Myeloma Market: By Route of Administration Segment Market Trends, Size, and Future Outlook
- By Route of Administration Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Route of Administration Segment Definitions, Technology Landscape
- By Route of Administration Segment Market Drivers
- Improved patient compliance
- Ease of self-administration
- By Route of Administration Segment Market Restraints
- Limitations of oral bioavailability
- Preference for injectable/IV formulations
Chapter 5. Multiple Myeloma Market: By Distribution Channel Segment Market Trends, Size, and Future Outlook
- By Distribution Channel Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Distribution Channel Segment Definitions, Technology Landscape
- By Distribution Channel Segment Market Drivers
- Increasing hospital purchases
- Rising online pharmacy adoption
- By Distribution Channel Segment Market Restraints
- High costs
- Lack of access in emerging markets
Chapter 6. Multiple Myeloma Market: By Line of Treatment Segment Market Trends, Size, and Future Outlook
- By Line of Treatment Segment Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Line of Treatment Segment Definitions, Technology Landscape
- By Line of Treatment Segment Market Drivers
- Increasing use of frontline therapies
- Growing demand for relapsed/refractory treatments
- By Line of Treatment Segment Market Restraints
- Low response rates
- Development of resistance
Chapter 7. Multiple Myeloma Market: Regional Market Trends, Size, and Future Outlook
- North America Market Size (US$), CAGR (%), and Future Outlook
- North America Market Size (US$), CAGR (%), and Forecast (2023-2031)
- North America Definitions, Technology Landscape
- North America Market Drivers
- High disease burden
- Favorable reimbursement
- North America Market Restraints
- Patent expirations
- Biosimilar competition
- Europe Market Size (US$), CAGR (%), and Future Outlook
- Europe Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Europe Definitions, Technology Landscape
- Europe Market Drivers
- Rising prevalence
- New product launches
- Europe Market Restraints
- Stringent regulations
- Pricing pressure
- Asia Pacific Market Size (US$), CAGR (%), and Future Outlook
- Asia Pacific Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Asia Pacific Definitions, Technology Landscape
- Asia Pacific Market Drivers
- Large patient pool
- Growing healthcare spending
- Asia Pacific Market Restraints
- Limited access
- Lack of reimbursement
- Rest of World Market Size (US$), CAGR (%), and Future Outlook
- Rest of World Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Rest of World Definitions, Technology Landscape
- Rest of World Market Drivers
- Increasing awareness
- Emerging economies
- Rest of World Market Restraints
- Weak healthcare infrastructure
- High cost of novel therapies
Chapter 8. Multiple Myeloma Market: Competitive Landscape
- Bristol Myers Squibb
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Takeda Pharmaceutical
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Janssen Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Amgen
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novartis
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AbbVie
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- GlaxoSmithKline
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Roche
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Merck
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Johnson & Johnson
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
US$ 16.6 billion in 2023
Rising incidence globally, Launch of novel therapies, Advances in combination treatment, Improved diagnosis, Rising pharmaceutical R&D spending, Growth opportunities in emerging markets
Low diagnosis rates, High treatment costs, Adverse effects of therapeutics, Patent expirations of top drugs
The immunomodulatory drugs (IMiDs) segment accounts for the largest share of the multiple myeloma market. IMiDs like Revlimid and Pomalyst are widely used for MM treatment.
Takeda, Janssen, Bristol Myers Squibb, Amgen, Novartis, AbbVie, GlaxoSmithKline, Roche, Merck, Johnson & Johnson
CAGR of 5.8% Market Size - US$ 26.1 billion in 2031
Aging population, Rising incidence rates, New drug launches, Advances in therapies, Improved diagnosis, Favorable reimbursement